* Amplicon Corp., of Stony Brook, N.Y., said U.S. patentNo. 5,436,142, covering representational differenceanalysis, a gene discovery technology, was issued.Amplicon licensed the patent from Cold Spring HarborLaboratory, of New York.

* AndCare Inc., of Research Triangle Park, N.C., wasissued U.S. patent No. 5,486,366 covering its lead-detection system.

* AntiCancer Inc., of San Diego, received allowance ofpatent for its MetaMouse cancer model, which is createdby implanting human tumors into immunodeficient mice.

* Celgene Corp., of Warren, N.J., was issued U.S. patentNo. 5,463,063 for a scaleable process to make high-puritythalidomide.

* Celtrix Pharmaceuticals Inc., of Santa Clara, Calif., wasissued U.S. patent Nos. 5,470,727; 5,470,727; and5,459,051 related to its IGF-BP3 complex, SomatoKine.

* HemaSure Inc., of Marlborough, Mass., was issuedU.S. patent No. 5,472,605 covering the LeukoNet Filter,which is used to remove leukocytes.

* ImmunoGen Inc., of Cambridge, Mass., was issuedU.S. patent No. 5,475,092 covering the therapeutic use ofanalogues and derivatives of its small molecule drug,DC1, in immunoconjugates.

* IntraBiotics Pharmaceuticals Inc., of Sunnyvale, Calif.,was issued U.S. patent No. 5,464,823 covering peptideantimicrobials called protegrins and their use in humans,animals and plants.

* NeXstar Pharmaceuticals Inc., of Boulder, Colo., wasissued U.S. patent No. 5,475,096 coveringoligonucleotides created and identified using its Selexcombinatorial chemistry technology.

* Sepracor Inc., of Marlborough, Mass., was awardedU.S. patent No. 5,470,868 covering the use of R-ondansetron as an antiemetic.

* Texas Biotechnology Corp., of Houston, was issuedU.S. patent No. 5,464,853 covering novel compoundsthat antagonize endothelin receptors.

(c) 1997 American Health Consultants. All rights reserved.